<DOC>
	<DOC>NCT01706783</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092) compared to once daily Norditropin NordiFlex® in adults with growth hormone deficiency (GHD).</brief_summary>
	<brief_title>A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adults with GHD as defined in the consensus guidelines for the diagnosis and treatment of adults with GHD Stable human growth hormone (hGH) replacement therapy for at least 3 months Participation in another clinical trial within 3 months or receipt of any investigational medicinal product within 3 months prior to randomisation Active malignant disease or malignant disease within the last 5 years with exception of fully treated local basal cell carcinoma or carcinoma in situ of cervix Proliferative retinopathy judged by retinaphoto within the last year only with concomitant diabetes Heart insufficiency, New York Heart Association (NYHA) class above 2 Adults with GHD with poorly controlled diabetes mellitus with a glycosylated haemoglobin (HbA1c) 64 mmol/mol (8.0%) and/or insulin treatment Stable pituitary replacement therapy for less than 3 months</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>